MRKR Marker Therapeutics Inc
Price (delayed)
$2.7
Market cap
$24.09M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.18
Enterprise value
$16.29M
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy
Highlights
Marker Therapeutics's gross profit has increased by 12% QoQ
MRKR's revenue is up by 12% since the previous quarter
The EPS has dropped by 84% since the previous quarter but it is up by 24% year-on-year
MRKR's net income has dropped by 83% since the previous quarter but it is up by 22% year-on-year
Marker Therapeutics's equity has decreased by 49% YoY and by 18% from the previous quarter
Marker Therapeutics's quick ratio has decreased by 23% YoY and by 9% from the previous quarter
Key stats
What are the main financial stats of MRKR
Market
Valuations
Earnings
Shares outstanding
8.92M
Market cap
$24.09M
Enterprise value
$16.29M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.48
Price to sales (P/S)
6.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.37
Revenue
$3.73M
EBIT
-$10.37M
EBITDA
-$10.37M
Free cash flow
-$10.9M
Per share
Balance sheet
Liquidity
EPS
-$1.18
Free cash flow per share
-$1.22
Book value per share
$1.09
Revenue per share
$0.42
TBVPS
$1.31
Total assets
$11.68M
Total liabilities
$1.97M
Debt
$0
Equity
$9.7M
Working capital
$9.7M
Debt to equity
0
Current ratio
5.92
Quick ratio
5.22
Net debt/EBITDA
0.75
Margins
Efficiency
Dividend
EBITDA margin
-278.1%
Gross margin
100%
Net margin
-278.2%
Operating margin
-295%
Return on assets
-66.5%
Return on equity
-79.4%
Return on invested capital
-7,659.2%
Return on capital employed
-106.8%
Return on sales
-278.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRKR stock price
How has the Marker Therapeutics stock price performed over time
Intraday
-2.88%
1 week
-13.74%
1 month
-29.32%
1 year
-53.21%
YTD
-50.91%
QTD
-50.28%
Financial performance
How have Marker Therapeutics's revenue and profit performed over time
Revenue
$3.73M
Gross profit
$3.73M
Operating income
-$10.99M
Net income
-$10.37M
Gross margin
100%
Net margin
-278.2%
MRKR's net income has dropped by 83% since the previous quarter but it is up by 22% year-on-year
The company's net margin has shrunk by 63% QoQ but it rose by 21% YoY
Marker Therapeutics's operating income has increased by 36% YoY and by 14% from the previous quarter
MRKR's operating margin is up by 36% year-on-year and by 24% since the previous quarter
Growth
What is Marker Therapeutics's growth rate over time
Valuation
What is Marker Therapeutics stock price valuation
P/E
N/A
P/B
2.48
P/S
6.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.37
The EPS has dropped by 84% since the previous quarter but it is up by 24% year-on-year
Marker Therapeutics's equity has decreased by 49% YoY and by 18% from the previous quarter
The P/B is 27% below the last 4 quarters average of 3.5 but 7% above the 5-year quarterly average of 2.4
MRKR's P/S is 94% below its 5-year quarterly average of 108.7 and 49% below its last 4 quarters average of 13.1
MRKR's revenue is up by 12% since the previous quarter
Efficiency
How efficient is Marker Therapeutics business performance
The ROE has dropped by 116% since the previous quarter and by 16% year-on-year
The ROA has plunged by 113% from the previous quarter and by 58% YoY
The ROS has dropped by 63% since the previous quarter but it is up by 21% year-on-year
Dividends
What is MRKR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRKR.
Financial health
How did Marker Therapeutics financials performed over time
The total assets has contracted by 47% YoY and by 17% from the previous quarter
MRKR's total liabilities is down by 32% year-on-year and by 14% since the previous quarter
The company's debt is 100% lower than its equity
Marker Therapeutics's equity has decreased by 49% YoY and by 18% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.